Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class?
Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2036|47|4|539-540
ISSN： 0269-2813
Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.4, 2018-02, pp. : 539-540
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
